Checkpoint Therapeutics Inc (CKPT)

Dec 18, 2024, 1:19 PM EST - 4 weeks ago

Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval

Dec 13, 2024, 6:15 PM EST - 5 weeks ago

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

FBIO

Nov 14, 2024, 4:20 PM EST - 2 months ago

Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date

Nov 12, 2024, 4:30 PM EST - 2 months ago

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

FBIO

Sep 16, 2024, 7:30 AM EDT - 4 months ago

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

FBIO

Sep 4, 2024, 8:00 AM EDT - 4 months ago

Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

FBIO

Aug 27, 2024, 4:50 PM EDT - 5 months ago

Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success

Aug 12, 2024, 8:30 AM EDT - 5 months ago

Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates

FBIO

Jul 25, 2024, 7:30 AM EDT - 6 months ago

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

FBIO

Jul 15, 2024, 8:00 AM EDT - 6 months ago

GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research

FBIO

Jul 2, 2024, 8:00 AM EDT - 7 months ago

Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FBIO

Jul 2, 2024, 7:00 AM EDT - 7 months ago

Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab

FBIO

Jun 24, 2024, 7:30 AM EDT - 7 months ago

Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

FBIO

Jun 5, 2024, 5:34 AM EDT - 8 months ago

Lifshitz Law PLLC Announces Investigations of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), Fox Factory Holding Corp. (NASDAQ: FOXF), Snowflake Inc. (NYSE: SNOW), and Nextdoor Holdings, Inc. (NYSE: KIND)

FOXF KIND SNOW

Jun 3, 2024, 12:21 PM EDT - 8 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

Jun 3, 2024, 12:15 PM EDT - 8 months ago

CKPT DEADLINE UPDATE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Jun 2, 2024, 11:00 AM EDT - 8 months ago

IMPORTANT DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Jun 1, 2024, 11:00 AM EDT - 8 months ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

May 31, 2024, 11:00 AM EDT - 8 months ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

May 31, 2024, 9:40 AM EDT - 8 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

May 24, 2024, 12:00 PM EDT - 8 months ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

May 13, 2024, 8:30 AM EDT - 8 months ago

Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

FBIO

May 10, 2024, 8:30 AM EDT - 9 months ago

Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates

FBIO

Apr 13, 2024, 8:00 PM EDT - 9 months ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Apr 12, 2024, 4:00 PM EDT - 10 months ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

Apr 12, 2024, 5:00 AM EDT - 10 months ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Apr 10, 2024, 1:22 PM EDT - 10 months ago

The Law Offices of Frank R. Cruz Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

Mar 22, 2024, 8:30 AM EDT - 10 months ago

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

FBIO

Mar 18, 2024, 8:00 AM EDT - 10 months ago

Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

Jan 29, 2024, 8:00 AM EST - 1 year ago

Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market

Jan 11, 2024, 8:15 AM EST - 1 year ago

Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

Dec 18, 2023, 8:43 AM EST - 1 year ago

Checkpoint Therapeutics slides after US FDA declines cancer therapy approval

Dec 18, 2023, 7:00 AM EST - 1 year ago

U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer

Dec 5, 2023, 8:30 AM EST - 1 year ago

Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance

Nov 13, 2023, 5:00 PM EST - 1 year ago

Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Oct 18, 2023, 8:30 AM EDT - 1 year ago

Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer

Oct 2, 2023, 12:53 PM EDT - 1 year ago

Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds

Sep 21, 2023, 8:30 AM EDT - 1 year ago

Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference

Sep 6, 2023, 8:30 AM EDT - 1 year ago

Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference